Search

AstraZeneca PLC

Cerrado

SectorSalud

12,818 0.42

Resumen

Variación precio

24h

Actual

Mínimo

12736

Máximo

12970

Métricas clave

By Trading Economics

Ingresos

211M

3.1B

Ventas

1.3B

15B

P/B

Media del Sector

32.273

37.257

Rentabilidad por dividendo

2.46

Margen de beneficio

21.067

Empleados

94,300

EBITDA

18M

5.1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+7.9% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.46%

2.94%

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

31B

198B

Apertura anterior

12817.58

Cierre anterior

12818

Noticias sobre sentimiento de mercado

By Acuity

32%

68%

115 / 371 Clasificación en Healthcare

AstraZeneca PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

8 sept 2025, 16:13 UTC

Principales Movimientos del Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

29 jul 2025, 08:08 UTC

Ganancias

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 jul 2025, 06:46 UTC

Ganancias

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

1 oct 2025, 09:05 UTC

Acciones populares

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 sept 2025, 09:33 UTC

Charlas de Mercado

AstraZeneca's Direct NYSE Listing May Hint at Future Intentions -- Market Talk

29 sept 2025, 09:08 UTC

Ganancias
Acciones populares

Stocks to Watch Monday: Carnival, GSK, Alibaba -- WSJ

8 ago 2025, 10:51 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1 ago 2025, 11:10 UTC

Acciones populares

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 jul 2025, 11:02 UTC

Ganancias

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 jul 2025, 11:02 UTC

Ganancias

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 jul 2025, 11:01 UTC

Ganancias

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 jul 2025, 11:00 UTC

Ganancias

AstraZeneca Results: H1 and Q2 2025

29 jul 2025, 08:00 UTC

Charlas de Mercado
Ganancias

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 jul 2025, 07:53 UTC

Charlas de Mercado
Ganancias

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 jul 2025, 07:26 UTC

Charlas de Mercado
Ganancias

AstraZeneca Shares Look Undervalued -- Market Talk

29 jul 2025, 06:03 UTC

Ganancias

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 jul 2025, 06:03 UTC

Ganancias

AstraZeneca 2Q Total Revenue $14.46B

29 jul 2025, 06:03 UTC

Ganancias

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 jul 2025, 06:03 UTC

Ganancias

AstraZeneca 2Q Core EPS $2.17

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Backs 2025 View

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Rev $14.46B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Adj EPS $2.17

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Net Pft $2.45B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Oper Pft $3.51B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q EPS $1.57

28 jul 2025, 10:51 UTC

Charlas de Mercado

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

AstraZeneca PLC Esperado

Precio Objetivo

By TipRanks

7.9% repunte

Estimación a 12 meses

Media 13,789.54 GBX  7.9%

Máximo 18,000 GBX

Mínimo 10,900 GBX

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

10

Comprar

3

Mantener

0

Vender

Sentimiento

By Acuity

115 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat